Compile Data Set for Download or QSAR
Report error Found 267 Enz. Inhib. hit(s) with all data for entry = 11958
TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665021(US20240116892, Compound I-1)
Affinity DataKd:  3.00E+3nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665022(US20240116892, Compound I-2)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665023(US20240116892, Compound I-3)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665024(US20240116892, Compound I-4)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665025(US20240116892, Compound I-5)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665026(US20240116892, Compound I-6)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665027(US20240116892, Compound I-7)
Affinity DataKd:  3.00E+3nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665028(US20240116892, Compound I-8)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665029(US20240116892, Compound I-9)
Affinity DataKd:  3.00E+3nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665030(US20240116892, Compound I-10)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665031(US20240116892, Compound I-11)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665032(US20240116892, Compound I-12)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665033(US20240116892, Compound I-13)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665034(US20240116892, Compound I-14)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665035(US20240116892, Compound I-15)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665036(US20240116892, Compound I-16)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665037(US20240116892, Compound I-17)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665038(US20240116892, Compound I-18)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665039(US20240116892, Compound I-19)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665040(US20240116892, Compound I-20)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665041(US20240116892, Compound I-21)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665042(US20240116892, Compound I-22-a)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665043(US20240116892, Compound I-22-b)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665044(US20240116892, Compound I-23)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665045(US20240116892, Compound I-24)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665046(US20240116892, Compound I-25)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665047(US20240116892, Compound I-26)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665048(US20240116892, Compound I-27-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665049(US20240116892, Compound I-27-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665050(US20240116892, Compound I-28)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665051(US20240116892, Compound I-29-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665052(US20240116892, Compound I-29-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665053(US20240116892, Compound I-30)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665054(US20240116892, Compound I-31)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665055(US20240116892, Compound I-33-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665056(US20240116892, Compound I-33-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665057(US20240116892, Compound I-34-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665058(US20240116892, Compound I-34-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665059(US20240116892, Compound I-35-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665060(US20240116892, Compound I-35-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665061(US20240116892, Compound I-36-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665062(US20240116892, Compound I-36-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665063(US20240116892, Compound I-37-a)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665064(US20240116892, Compound I-37-b)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665065(US20240116892, Compound I-38)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665066(US20240116892, Compound I-39)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665067(US20240116892, Compound I-40)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665068(US20240116892, Compound I-41-a)
Affinity DataKd:  3.00E+3nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665069(US20240116892, Compound I-41-b)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics, Inc.

US Patent
LigandPNGBDBM665070(US20240116892, Compound I-42)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1 domain-catalytic, Y1007F, Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HE...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 267 total ) | Next | Last >>
Jump to: